AstraZeneca Pharma India share news and announcements
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India share news and announcements
671 announcements, routine notices left out, newest first. Page 11 of 14.
Sep 2015
4 Sep · Disclosure of Voting Pattern - Clause 35A
Aug 2015
Jul 2015
Jun 2015
9 Jun · Code of Conduct under SEBI(PIT) Reg., 2015
May 2015
Apr 2015
Mar 2015
9 Mar · Legal
Spurt in Volume : Substantial increase in trading volumes have been observed in AstraZeneca Pharma India Limited.. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. AstraZeneca Pharma India Limited has vide its letter inter-alia stated, "We have no information/announcement (including impending announcement) which in the Company's opinion may have a bearing on the price/volume behavior in the scrip."
Feb 2015
10 Feb · Legal
Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to a news item captioned "AstraZeneca to buy Actavis lung drugs". The Company has clarified that "The said news does not pertain to AstraZeneca Pharma India Limited. Rather, it comes under a separate legal entity established under the laws outside India".6 Feb · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with respect to recent news item captioned "AstraZeneca to buy Actavis lung drugs". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Jan 2015
Nov 2014
24 Nov · Management
Mr. Robert Haxton has resigned as the Wholetime Director of the Company. The Board has accepted the resignation of Mr. Haxton and that he would be relieved from the said position, effective December 14, 2014.3 Nov · Management
Board appointed Ms. Rebekah Martin as an Additional Director of the Company, effective November 03, 2014.
Oct 2014
16 Oct · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014. Further the 'Trading Window' shall remain closed for all Specified Persons, from October 16, 2014 to November 4, 2014 (both days inclusive) in terms of Company - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992.13 Oct · Legal
Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to a news item captioned "HC stays AstraZeneca s proposed delisting". The Company has clarified that "As regards Para 4 of the News Article, to the best of our understanding and as per the e-mail communication received from M/s. Res Legal, the law-firm representing the Company before Bombay High Court, the Petition was heard by the Court and disposed of finally. We are awaiting for a copy of the Order in this regard and upon receipt, we will have the same submitted to your exchange".10 Oct · Legal
Exchange has sought clarification from AstraZeneca Pharma India Limited with reference to recent news item which appeared in the "Mint" dated October 10, 2014, Page No. 10, captioned "HC stays AstraZeneca s proposed delisting". In this regard, you are advised to provide clarification/confirmation on the news item in detail including the following:a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement.1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2014
4 Sep · Address Change
Registered Office of the Company has been shifted from 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560024 to Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560045.
Aug 2014
28 Aug · Meeting
Share Transfer Books and Register of Members of the Company will remain closed from September 22, 2014 to September 30, 2014 (both days inclusive), in connection with the Annual General Meeting of the Company to be held on September 30, 2014,13 Aug · Board meeting
Board of Directors considered, inter alia, the following; 1. The Board noted and confirmed the appointment of Mr.Rajesh Marwaha as the Chief Financial Officer of the Company, effective August 04, 2014. 2. Approved the appointment of Mr. Anantha Murthy N as the Legal Counsel and Company Secretary and also designated him as the Compliance Officer of the Company. Prior to the above appointment he was the Legal Counsel and Associate Company Secretary.1 Aug · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2014. The 'Trading Window' shall remain closed for all Specified Persons, from August 1, 2014 to August 13, 2014 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Preventiion of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider trading) Regulations, 1992.1 Aug · Management
Mr. Pawan Singhal has resigned from the services of the Company and has accordingly ceased to be its Company Secretary and Compliance Officer, effective July 31,2014.
Jun 2014
May 2014
30 May · Board meeting
In view of absence of profits for the year ended March 31, 2014, and to conserve resources for future growth, the Board has not recommended any dividend on equity shares for the Financial Year ended March 31, 2014.22 May · Board meeting
For considering Audited Financial Results of the Company, for the last quarter and financial year ended March 31, 2014 & may also consider 'recommendation of dividend' for the financial year ended March 31, 2014.5 May · Board meeting
Board of Directors of the Company at its meeting held on May 05, 2014, inter alia, has approved seeking approval of shareholders of the Company through Postal Ballot for the voluntary delisting of equity shares of the Company proposed by AstraZeneca Pharmaceuticals AB, Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.2 May · Board meeting
To consider inter-alia seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.
Apr 2014
15 Apr · Board meeting
Board of Directors of the Company at its meeting held on April 15, 2014, deferred consideration of seeking approval of shareholders of the Company through Postal Ballot for the delisting of equity shares of the Company proposed by the Promoters of the Company, in the light of discussions with ICICI Securities Limited, the Manager and Walker Chandoik & Co LLP, the Valuer and pending their response to the clarifications and explanations sought from them.11 Apr · Board meeting
To consider inter-alia, seeking approval of shareholders of the Company through Postal Ballot, for the voluntary delisting proposed by AstraZeneca Pharmaceuticals AB Sweden, Promoter of the Company, in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.
Mar 2014
18 Mar · Voluntary Delisting
Pursuant to and in accordance with Regulation 8(1)(a) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, the delisting proposal received from AstraZeneca Pharmaceuticals AB, Sweden, the promoter of the Company, vide their letter dated March 01, 2014, was considered and approved by the Board of the Company at its meeting held on March 15, 2014.5 Mar · Board meeting
Board of Directors met on March 05, 2014 to consider the Delisting Proposal. After discussion, it was decided to seek additional information from the Promoter - AstraZeneca Pharmaceuticals AB, Sweden (AZP AB). Pending receipt of such additional information, consideration of the Promoter's letter dated March 01, 2014 was deferred.3 Mar · Board meeting
To consider the Delisting Proposal and Matters incidental hereto.
Feb 2014
Jan 2014
31 Jan · Legal
Exchange had sought clarification from AstraZeneca Pharma India Limited with respect to a news item captioned "'AstraZeneca to close down Banglore R&D centre". The Company has clarified that "AstraZeneca R&D Centre referred to in news is not a part of the listed legal entity in India AstraZeneca Pharma India Limited. Rather, it comes under a separate legal entity which is a wholly owned subsidiary of AstraZeneca group".